<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>34(10)</volume><submitter>Schmidt VF</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>To evaluate the safety and clinical outcome of bleomycin electrosclerotherapy (BEST) for treating extracranial slow-flow malformations.&lt;h4>Methods&lt;/h4>In this retrospective investigation of a multicenter cohort presenting symptomatic slow-flow malformations, patient records were analyzed with respect to procedural details and complications. A treatment-specific, patient-reported questionnaire was additionally evaluated, obtained 3-12 months after the last treatment, to assess the subjective outcomes, including mobility, aesthetic aspects, and pain, as well as the occurrence of postprocedural skin hyperpigmentation. All outcome parameters were compared according to patients' age.&lt;h4>Results&lt;/h4>Overall, 325 BEST treatments were performed in 233 patients after intralesiona</pubmed_abstract><journal>European radiology</journal><pagination>6425-6434</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11399160</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children.</pubmed_title><pmcid>PMC11399160</pmcid><pubmed_authors>Sint A</pubmed_authors><pubmed_authors>Ocal O</pubmed_authors><pubmed_authors>Ricke J</pubmed_authors><pubmed_authors>Wildgruber M</pubmed_authors><pubmed_authors>Mansour N</pubmed_authors><pubmed_authors>Wohlgemuth WA</pubmed_authors><pubmed_authors>Schmidt VF</pubmed_authors><pubmed_authors>Goldann C</pubmed_authors><pubmed_authors>Hengst S</pubmed_authors><pubmed_authors>von der Heydt S</pubmed_authors><pubmed_authors>Meyer L</pubmed_authors><pubmed_authors>Obereisenbuchner F</pubmed_authors><pubmed_authors>Umutlu MR</pubmed_authors><pubmed_authors>Cangir O</pubmed_authors><pubmed_authors>Seidensticker M</pubmed_authors><pubmed_authors>Rudolph J</pubmed_authors><pubmed_authors>Brill R</pubmed_authors><pubmed_authors>Haberle B</pubmed_authors><pubmed_authors>Puhr-Westerheide D</pubmed_authors><pubmed_authors>Waner M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children.</name><description>&lt;h4>Objectives&lt;/h4>To evaluate the safety and clinical outcome of bleomycin electrosclerotherapy (BEST) for treating extracranial slow-flow malformations.&lt;h4>Methods&lt;/h4>In this retrospective investigation of a multicenter cohort presenting symptomatic slow-flow malformations, patient records were analyzed with respect to procedural details and complications. A treatment-specific, patient-reported questionnaire was additionally evaluated, obtained 3-12 months after the last treatment, to assess the subjective outcomes, including mobility, aesthetic aspects, and pain, as well as the occurrence of postprocedural skin hyperpigmentation. All outcome parameters were compared according to patients' age.&lt;h4>Results&lt;/h4>Overall, 325 BEST treatments were performed in 233 patients after intralesiona</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2026-06-02T23:38:24.902Z</modification><creation>2025-04-05T18:42:28.02Z</creation></dates><accession>S-EPMC11399160</accession><cross_references><pubmed>38627287</pubmed><doi>10.1007/s00330-024-10723-6</doi></cross_references></HashMap>